Bejelentkezés Regisztrálj ingyen

OncoSec Medical Inc Beta

Mi az OncoSec Medical Inc Beta?

A Beta az OncoSec Medical Inc - 0.00

Mi a Beta meghatározása?



A BETA azt jelzi, hogy az állomány több-kevésbé volatilis, mint a piac egésze. Az 1-nél kevesebb béta azt jelzi, hogy az állomány kevésbé ingadozó, mint a piac, míg az 1-nél nagyobb béta azt jelzi, hogy az állomány volatilisabb. A volatilitást az átlag körüli ár ingadozásaként méri.

Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.

Beta a Health Care szektor a NASDAQ-on cégekben a OncoSec Medical Inc -hoz képest

Mit csinál OncoSec Medical Inc?

oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar

beta -hoz hasonló cégek OncoSec Medical Inc